PDF factsheet
      Z

combined BRAF-MEK inhibitors in melanoma for adjuvant setting, clinical trials results

trametinib and dabrafenib versus placebo
COMBI-AD, 2017
NCT01682083
dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months
versus
placebo
Patients with completely resected, histologically confirmed, BRAF V600E/K mutation-positive, high-risk [Stage IIIa (lymph node metastasis >1 mm), IIIb or IIIc] cutaneous melanomadouble-blind
trametinib and dabrafenib versus SOC
COMBI neo, 2018
NCT02231775

versus

  Options


in first

in second

  Filter